Találati lista | Tudóstér

001-es BibID:	BIBFORM081810
035-os BibID:	(cikkazonosító)1834 (WoS)000502294400077 (Scopus)85091254940 (PMID)31683969
Első szerző:	Pollesello, Piero
Cím:	Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline? / Piero Pollesello, Tuvia Ben Gal, Dominique Bettex, Vladimir Cerny, Josep Comin-Colet, Alexandr A. Eremenko, Dimitrios Farmakis, Francesco Fedele, Cândida Fonseca, Veli-Pekka Harjola, Antoine Herpain, Matthias Heringlake, Leo Heunks, Trygve Husebye, Visnja Ivancan, Kristian Karason, Sundeep Kaul, Jacek Kubica, Alexandre Mebazaa, Henning Mølgaard, John Parissis, Alexander Parkhomenko, Pentti Põder, Gerhard Pölzl, Bojan Vrtovec, Mehmet B. Yilmaz, Zoltan Papp
Dátum:	2019
ISSN:	2077-0383
Megjegyzések:	Both acute and advanced heart failure are an increasing threat in term of survival, quality of life and socio-economical burdens. Paradoxically, the use of successful treatments for chronic heart failure can prolong life but-per definition-causes the rise in age of patients experiencing acute decompensations, since nothing at the moment helps avoiding an acute or final stage in the elderly population. To complicate the picture, acute heart failure syndromes are a collection of symptoms, signs and markers, with different aetiologies and different courses, also due to overlapping morbidities and to the plethora of chronic medications. The palette of cardio- and vasoactive drugs used in the hospitalization phase to stabilize the patient's hemodynamic is scarce and even scarcer is the evidence for the agents commonly used in the practice (e.g. catecholamines). The pipeline in this field is poor and the clinical development chronically unsuccessful. Recent set backs in expected clinical trials for new agents in acute heart failure (AHF) (omecamtiv, serelaxine, ularitide) left a field desolately empty, where only few drugs have been approved for clinical use, for example, levosimendan and nesiritide. In this consensus opinion paper, experts from 26 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, The Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, Turkey, U.K. and Ukraine) analyse the situation in details also by help of artificial intelligence applied to bibliographic searches, try to distil some lesson-learned to avoid that future projects would make the same mistakes as in the past and recommend how to lead a successful development project in this field in dire need of new agents.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk acute heart failure advanced heart failure clinical development levosimendan regulatory clinical trials short-term hemodynamic therapy
Megjelenés:	Journal of Clinical Medicine. - 8 : 11 (2019), p. 1-18. -
További szerzők:	Ben Gal, Tuvia Bettex, Dominique Cerny, Vladimir Comin-Colet, Josep Eremenko, Alexandr A. Farmakis, Dimitrios Fedele, Francesco Fonseca, Candida Harjola, Veli-Pekka Herpain, Antoine Heringlake, Matthias Heunks, Leo Husebye, Trygve Ivancan, Visnja Karason, Kristian Kaul, Sundeep Kubica, Jacek Mebazaa, Alexandre Mølgaard, Henning Parissis, John Parkhomenko, Alexander Põder, Pentti Pölzl, Gerhard Vrtovec, Bojan Yilmaz, Mehmet Birhan Papp Zoltán (1965-) (kardiológus, élettanász)
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: